 Drug Administration Schedule
"Drug Administration Schedule" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
| Descriptor ID |
D004334
|
| MeSH Number(s) |
E02.319.283
|
| Concept/Terms |
Drug Administration Schedule- Drug Administration Schedule
- Administration Schedule, Drug
- Administration Schedules, Drug
- Drug Administration Schedules
- Schedule, Drug Administration
- Schedules, Drug Administration
|
Below are MeSH descriptors whose meaning is more general than "Drug Administration Schedule".
Below are MeSH descriptors whose meaning is more specific than "Drug Administration Schedule".
This graph shows the total number of publications written about "Drug Administration Schedule" by people in this website by year, and whether "Drug Administration Schedule" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 | | 1997 | 0 | 8 | 8 | | 1998 | 0 | 5 | 5 | | 1999 | 0 | 8 | 8 | | 2000 | 0 | 6 | 6 | | 2001 | 0 | 8 | 8 | | 2002 | 0 | 10 | 10 | | 2003 | 0 | 13 | 13 | | 2004 | 0 | 16 | 16 | | 2005 | 0 | 18 | 18 | | 2006 | 1 | 22 | 23 | | 2007 | 0 | 33 | 33 | | 2008 | 0 | 27 | 27 | | 2009 | 0 | 26 | 26 | | 2010 | 0 | 30 | 30 | | 2011 | 0 | 31 | 31 | | 2012 | 0 | 28 | 28 | | 2013 | 0 | 31 | 31 | | 2014 | 0 | 37 | 37 | | 2015 | 0 | 29 | 29 | | 2016 | 0 | 26 | 26 | | 2017 | 0 | 43 | 43 | | 2018 | 2 | 33 | 35 | | 2019 | 0 | 28 | 28 | | 2020 | 0 | 14 | 14 | | 2021 | 1 | 13 | 14 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 8 | 8 | | 2025 | 0 | 6 | 6 | | 2026 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Administration Schedule" by people in Profiles.
-
Major A, Ma E, Masaquel A, Tsang M, Di M, Kaur S, Pophali P, Werner S, Bungay R, Latrémouille-Viau D, Guerin A, Reyes C, Wu M, Cassoli L, Torka P. Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. Oncologist. 2026 Jun 06; 31(7).
-
Connery L, Rosenstock J, Rasouli N, Cheng AYY, Liebl A, Wang Q, Pires V, Knights A, Davidson MB, Child CJ. Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes. Diabetes Obes Metab. 2026 Jul; 28(7):6217-6224.
-
Eichenfield LF, Gonzalez ME, Boguniewicz M, Funk T, Hebert AA, Prajapati VH, Kindred C, Serrao R, Swanson L, Krupa D, Snyder S, Seal MS, Hanna D, Burnett P, Berk DR. Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5?Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). Pediatr Dermatol. 2026 May-Jun; 43(3):642-649.
-
Ustianowski A, Levin MJ, De Wit S, Launay O, Veekmans B, Rampling T, Sullivan JG, Vishnepolsky M, Wijewardane P, Fawadleh Y, Zhang H, Li M, Wickramarachchi D, Sharbaugh A, Beavon R, Thissen J, Hirao L, Dzutseva V, Seegobin S, Streicher K, Kiazand A, Esser MT, Chang LJ, Perez JL, Cohen TS. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. Clin Drug Investig. 2026 Feb; 46(2):207-219.
-
Boelig RC, Kavi A, Moore JL, Babineau DC, Metgud MC, Somannavar MS, Goudar SS, Derman RJ, Sunder Tikmani S, Saleem S, Goldenberg RL, Lokangaka AL, Tshefu AK, Bauserman MS, Mwenechanya M, Chomba E, Mazariegos M, Figueroa L, Krebs NF, Nyongesa P, Esamai F, Bucher S, Patel AB, Hibberd PL, Petri WA, Billah SM, Haque R, Koso-Thomas M, McClure EM, Carlo WA, Tita ATN. Timing of Prophylactic Intrapartum Azithromycin Administration and Efficacy in Prevention of Maternal and Infant Infections: A Secondary Analysis of a Randomized Controlled Trial. BJOG. 2026 Apr; 133(5):976-984.
-
Pillar S, Thomas A, Hassman LM, Chen H, Gangaputra S, Kopplin LJ, Boyd K, Moussa K, Pham DC, Chen K, Jackson NJ, Tsui E. Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Noninfectious Uveitis: A Multicenter Study. Ophthalmology. 2026 02; 133(2):187-193.
-
Feijóo B, Radi R, Lyon C. Reducing Anticoagulation Duration for Children After a Provoked Deep Venous Thrombosis. J Am Board Fam Med. 2025 Sep 15; 38(3):589-591.
-
Kurbatova EV, Dooley KE, Carr W, Stout JE, Nuermberger EL, Phillips PPJ, Scott NA, Upton CM, Ignatius E, Haas M, Walter ND, Traxler RM, Brown NE, Boyd R, Bryant KE, Dixon MG, Savic R, Eichberg C, Hesseling A, Bark C, Benator DA, Muzanyi G, Twycross NS, Fox GJ, Pierre S, Burzynski J, Fitzgerald DW. Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design. Contemp Clin Trials. 2025 Nov; 158:108075.
-
Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025 Apr 24; 392(16):1569-1581.
-
Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Velásquez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 05; 152:107875.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|